This study is testing an investigational drug called ALTB-268 for adults with moderate-to-severe ulcerative colitis (UC) whose disease has not improved with at least one other advanced biologic therapy. About 50 participants will receive weekly injections of ALTB-268 for 12 weeks…
Phase: PHASE2 • Sponsor: AltruBio Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC